EASD 2019 Both HF patients with and without T2DM showed about 25% reduction of worsening HF and CV death when treated with dapagliflozin in the DAPA-HF study, and symptoms improved.

Real-world data of the CHAMP-HF registry show that patients initiating sacubitril/valsartan experience improvements in KCCQ physical limitation and QoL domains during a median of 57 days.

ESC 2019 A strategy of early and sustained vasodilation in acute HF patients was unable to reduce all-cause death and rehospitalization for acute HF.

ESC 2019 The BB-meta-HF group combined double-blind, individual patient-level data and confirmed that beta-blockers are efficient in HFrEF patients in sinus rhythm with moderately-severe renal dysfunction.

ESC 2019 Early intensive and sustained vasodilation with individualized doses of well-characterized drugs in adults with AHF did not improve all-cause mortality and AHF hospitalizations.

ESC 2019 In HFrEF patients with and without diabetes, dapagliflozin therapy reduced the composite of CV death and worsening HF events compared to placebo.

ESC 2019 DAPA-HF evaluated dapagliflozin in addition to standard therapy in HFrEF patients with or without diabetes, and showed a risk reduction of 26% in worsening of HF and CV death.

ESC 2019 Sacubitril/valsartan was tested in HFpEF patients in the PARAGON-HF trial. The reduction in HF hospitalizations and CV death just missed significance, but heterogeneity was seen for the treatment effect.

ESC 2019 Sacubitril/valsartan, compared with valsartan, showed a non-significant reduction of 13% in HF hospitalization and CV death. Secondary outcomes suggest a benefit in some patients.

ESC HF 2019 Joost Beusekamp shares results of his study on the association between potassium levels measured daily during hospitalization, treatment with RAASi and outcomes in acute HF patients.

Persons with HIV-infection and HF showed a higher rate of SCD than uninfected subjects with HF. Better HIV disease control measures were associated with lower, but not background SCD rates.

Optimal doses of HF medication in women with HF is around 50% of currently recommended dose and women with HF benefit from lower doses of HF medication.